Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 25, 2008. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions.
- Share Purchase Price: £11.64 per share.
- Transaction Date: July 17, 2008.
- Dividend Re-investment Date: July 10, 2008.
Material Changes
The filing reports an increase in the ordinary share interests of four individuals through the GlaxoSmithKline Annual Investment Plan. These increases resulted from the re-investment of dividends paid on July 10, 2008.
| Individual | Shares Acquired |
|---|---|
| Mr A P Witty | 112 |
| Dr M M Slaoui | 247 |
| Mr M Dunoyer | 120 |
| Dr D Pulman | 182 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share purchases.
Investor Verification Points
- Verify the total number of shares held by the named directors following these transactions.
- Confirm the dividend amount per share implied by the re-investment at £11.64.
- Check subsequent filings for any further changes in director shareholdings.